French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.
AstraZeneca Defends Covid-19 Vaccine with Updated Data
AstraZeneca, Biomedical Advanced Research and Development Authority (BARDA), Coronavirus Disease 2019 (COVID-19), Covid-19 Data, COVID-19 Vaccines, Data Safety Monitoring Board (DSMB), Health Canada, Hospitalized COVID-19 Patients, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Oxford University, Symptomatic COVID-19 InfectionsAstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.
Shares of Mesoblast Limited were down more than 30% in trading following the company’s disappointing announcement regarding a stem-cell therapy trial in ventilator-dependent patients with Covid-19 patients who have moderate-to-severe acute respiratory distress syndrome.